Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET
NCT01994733Phase 2Completed
- Sponsor
- Unity Health Toronto
- Start
- Jan 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of calcium carbonate in hyperphosphatemia (2 arms), sponsored by Unity Health Toronto. Primary endpoint: Serum phosphate concentration at 26 weeks. Started Jan 2014; status: completed.
02
Drugs
calcium carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT01994733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994733.